1
Clinical Trials associated with Melan-A-EAA/ELA(Centre Hospitalier Universitaire Vaudois)Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant
The purpose of this study is to determine whether vaccination with melanoma antigen peptides [Melan-A/Mart-1 (both EAA and ELA), NY-ESO-1b analog, Long NY-ESO-1 LP and MAGE-A10] and Montanide, CpG adjuvants and low dose rIL-2 can induce an immune response in melanoma patients and to assess the safety of this vaccination.
100 Clinical Results associated with Melan-A-EAA/ELA(Centre Hospitalier Universitaire Vaudois)
100 Translational Medicine associated with Melan-A-EAA/ELA(Centre Hospitalier Universitaire Vaudois)
100 Patents (Medical) associated with Melan-A-EAA/ELA(Centre Hospitalier Universitaire Vaudois)
100 Deals associated with Melan-A-EAA/ELA(Centre Hospitalier Universitaire Vaudois)